1800 244 735

Helpline (02) 9874 9777

WAVE PRECISION-HD clinical trials stopped

An open letter to the Australian Huntington’s community following the 29 March 2021 press release from Wave Life Sciences:

On March 29, 2021, Wave Life Sciences issued a press release regarding their PRECISION-HD clinical trials, which are ongoing in Australia and several other countries globally. The key information from the press release is that for both of these trials (PRECISION-HD1 and PRECISION-HD2), the treatments appear not to be working effectively.

As a result of these findings, Wave will discontinue the treatment aspect of these two trials. Study visits will continue to gather important final data, and then Wave will end any further development of these two treatments. Although this is most disappointing, these trials have provided essential knowledge that will help to guide next steps in developing treatments for HD.

We as a community are grateful to the participants, their families and to the Australian site staff who have all worked so hard and given up so much of their time and effort to these two Wave trials. Australia has made key contributions to these trials, with sites in Perth, Brisbane, Sydney, and two in Melbourne.

Wave has developed a third treatment which has some key advantages over the first two. The good news is that Australia will be one of the countries participating in this third trial. Australian sites have yet to be determined.

For people with HD and their families, we share the disappointment in the news from both Wave and Roche.  However, several additional treatments are in the works, and a broad array of life sciences companies are working to rapidly start more potential treatment trials.

As more news comes to light about the Wave and Roche trials, we will organise an accessible way to communicate this important information to you, our community.

From your Australian HD medical clinicians, State-based HD Associations and Huntington’s researchers

 

 

 

 

 

 

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest News and Stories

PGT will be available for Huntington’s families

Published date: 18 May, 2021

Huntington’s families now have several options when considering when and how to have children. One of these options is PGD – Pre-implantation Genetic Diagnosis, sometimes known as PGT. This allows people to use IVF technology to ensure that only embryos without the HD-causing mutation are implanted, meaning that these children will grow up HD-free.

A 4000km cycle to Broome

Published date: 19 April, 2021

Erica and Bill are about to set off on a cycle to Broome. Erica will be the support driver for her partner Bill as they cover over 4000km to reach Broome in June. We are so grateful that you have chosen to fundraise for us.

OUR SUBMISSION to the Joint Standing Committee on the NDIS inquiry into Independent Assessments

Published date: 6 April, 2021

Huntington’s Associations in NSW/ACT, QLD, WA, SA/NT and TAS have partnered with other groups representing people with various neurological diseases to make a joint submission to the Joint Standing Committee on the National Disability Insurance Scheme inquiry into independent assessments under the NDIS. In summary, we do not support the introduction of independent assessments in ... Read more

WAVE PRECISION-HD clinical trials stopped

Published date: 6 April, 2021

An open letter to the Australian Huntington’s community following the 29 March 2021 press release from Wave Life Sciences: On March 29, 2021, Wave Life Sciences issued a press release regarding their PRECISION-HD clinical trials, which are ongoing in Australia and several other countries globally. The key information from the press release is that for ... Read more

An Open Letter to the Australian Huntington’s Community

Published date: 25 March, 2021

Since the news from Roche came out, Australian clinicians, state organisation leaders, and Huntington’s researchers have been meeting on teleconferences to discuss what this means for the Australian Huntington’s disease community.

Generation HD1 trial halted

Published date: 23 March, 2021

The Roche clinical trial called Phase III Generation HD1 has been halted, not by Roche, but by an independent data monitoring committee.